Cancer_Cell Profile Banner
Cancer Cell Profile
Cancer Cell

@Cancer_Cell

Followers
73K
Following
298
Media
2K
Statuses
7K

Cancer Cell provides a high-profile forum for showcasing advances in cancer research, with a strong emphasis on translational research.

Cambridge, MA, USA
Joined May 2012
Don't wanna be here? Send us removal request.
@Cancer_Cell
Cancer Cell
2 days
You don't have to wait any longer to read the November issue of Cancer Cell! Available now: https://t.co/iciZcIIT27
0
2
36
@Cancer_Cell
Cancer Cell
2 hours
Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer https://t.co/dw4oXgmM2g
0
1
4
@CelsiusOfficial
CELSIUS Energy Drink
2 months
Spritz Vibe. Limited Edition. Frosted over & fresh for the season, Spritz Vibe Sparkling Snowball Frost Limited Edition is here! CELSIUS. LIVE. FIT. GO.
534
738
11K
@Cancer_Cell
Cancer Cell
7 hours
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma https://t.co/tBugA9qp3D
0
2
17
@Cancer_Cell
Cancer Cell
9 hours
Save the date for Cell Symposia: Hallmarks of cancer 2026! 📆November 1–3, 2026 📍Sitges, Spain 🔗 https://t.co/oDCJr0tDsU @CellSymposia #CSHallmarks2026 #TumorImmunology #CancerNeuroscience #ImmunoOncology #PrecisionOncology #CancerMicrobiome #ClinicalOncology
0
0
6
@Cancer_Cell
Cancer Cell
21 hours
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer https://t.co/qdEE8z20N7
0
6
17
@Cancer_Cell
Cancer Cell
1 day
Protein-based classification reveals an immune-hot subtype in IDH mutant astrocytoma with worse prognosis https://t.co/54n7h1F9S9
0
9
33
@Cancer_Cell
Cancer Cell
1 day
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency https://t.co/66iPSJ7uCt
0
26
85
@Cancer_Cell
Cancer Cell
2 days
Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling https://t.co/WyuI2KhzmU
0
14
63
@Cancer_Cell
Cancer Cell
2 days
Long-range cholinergic input promotes glioblastoma progression https://t.co/APMwEo6uWC
0
11
46
@Cancer_Cell
Cancer Cell
5 days
Online Now: Remodeling of T and endothelial cells during total neoadjuvant therapy in rectal cancer https://t.co/6gy7zTpU3u
0
16
50
@Cancer_Cell
Cancer Cell
5 days
Online Now: Decoding the spatial dynamics of tumor and immune cell interactions in solid cancers https://t.co/Zh47HhAaMk
1
46
186
@Cancer_Cell
Cancer Cell
5 days
Online Now: Cellular senescence in precancer lesions and early-stage cancers https://t.co/QR4tyYyKuK
1
38
130
@Cancer_Cell
Cancer Cell
6 days
Online Now: Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions
Tweet card summary image
cell.com
By single-cell and spatial transcriptomics analysis, Peng et al. reveal that alveolar progenitors are the earliest predecessor of LUAD and reside in epithelial-proinflammatory niches that are more...
0
26
79
@Cancer_Cell
Cancer Cell
6 days
Online Now: Toward a new standard: Sequential multi-agent neoadjuvant chemotherapy in resectable pancreatic cancer https://t.co/xorddfxYiC
0
3
10
@Cancer_Cell
Cancer Cell
13 days
Online Now: Fusobacterium, quiescent niches, and therapy response in colorectal cancer
1
8
24
@Cancer_Cell
Cancer Cell
19 days
Online Now: The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression https://t.co/K0ZWhTuw3J
0
16
51
@Cancer_Cell
Cancer Cell
19 days
Online Now: Functional pseudo-synapses: A new nexus in extracranial cancer https://t.co/OVzenTusAJ
0
9
47
@Cancer_Cell
Cancer Cell
19 days
Online Now: RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition https://t.co/YCx3Do8gN2
0
14
56
@Cancer_Cell
Cancer Cell
20 days
Online Now: TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study https://t.co/kCijE6C3TE
0
6
23